Dr. Kasarskis leads collaborative projects aimed at new therapeutics and diagnostics, and his research focuses on developing and applying technology to several areas including pathogen surveillance, pharmacogenomics, and the genetics of sleep. He has over a decade of experience managing research and technology development projects in software engineering, drug development, human and mouse genetics, and other biological research applications. Prior to Mount Sinai, he held positions at Pacific Biosciences, Sage Bionetworks, and Merck. Dr. Kasarskis holds a PhD in Molecular and Cellular Biology from UC Berkeley as well as a BS in Biology and a BA in Chemistry from the University of Kentucky.
Finding The Molecules Behind Clinical Presentation
Clinical heterogeneity driven by environment and genetics is ubiquitous and drives work and cost in health care delivery. This heterogeneity is a proximal result of the state of molecular networks in patients. In the Mount Sinai Health System we are streamlining paths to describing and targeting the network state of unique patient subsets.
The value of data in healthcare is undeniable and realized when raw information is successfully converted into knowledge that changes clinical practice. To drive value improvements and ensure that the right patient receives the right care requires the right data in combination with the right data analytics. This session will cover various aspects and challenges of data science in hospitals and health systems that drive healthcare with better outcomes.